Brokerages Anticipate Gilead Sciences, Inc. (NASDAQ:GILD) Will Announce Quarterly Sales of $6.14 Billion

Wall Street brokerages forecast that Gilead Sciences, Inc. (NASDAQ:GILD) will report sales of $6.14 billion for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Gilead Sciences’ earnings, with estimates ranging from $5.98 billion to $6.32 billion. Gilead Sciences posted sales of $6.58 billion in the same quarter last year, which would indicate a negative year over year growth rate of 6.7%. The firm is expected to issue its next quarterly earnings report on Wednesday, October 27th.

According to Zacks, analysts expect that Gilead Sciences will report full-year sales of $25.05 billion for the current year, with estimates ranging from $24.61 billion to $25.21 billion. For the next fiscal year, analysts forecast that the business will report sales of $24.33 billion, with estimates ranging from $22.28 billion to $25.48 billion. Zacks’ sales averages are an average based on a survey of research firms that cover Gilead Sciences.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, July 29th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.76 by $0.11. Gilead Sciences had a return on equity of 55.94% and a net margin of 19.38%. The firm had revenue of $6.22 billion during the quarter, compared to analysts’ expectations of $6.15 billion. During the same period in the prior year, the business earned $1.11 EPS.

A number of equities analysts have recently issued reports on the company. Royal Bank of Canada reiterated a “buy” rating and issued a C$84.00 price objective on shares of Gilead Sciences in a report on Monday, August 23rd. Morgan Stanley restated a “buy” rating and set a $83.00 target price on shares of Gilead Sciences in a report on Friday, August 27th. Oppenheimer began coverage on Gilead Sciences in a report on Monday, June 28th. They set a “buy” rating and a $100.00 target price for the company. Zacks Investment Research upgraded Gilead Sciences from a “sell” rating to a “hold” rating and set a $72.00 target price for the company in a report on Tuesday, August 10th. Finally, BMO Capital Markets increased their price objective on Gilead Sciences from $67.00 to $72.00 and gave the stock a “market perform” rating in a report on Friday, July 30th. Nine analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of “Buy” and an average target price of $104.74.

Shares of GILD traded up $0.01 during midday trading on Tuesday, reaching $70.45. The stock had a trading volume of 5,484,337 shares, compared to its average volume of 7,338,444. The company’s 50-day moving average is $70.17 and its 200 day moving average is $67.59. Gilead Sciences has a 12-month low of $56.56 and a 12-month high of $73.34. The company has a current ratio of 1.36, a quick ratio of 1.19 and a debt-to-equity ratio of 1.42. The company has a market capitalization of $88.33 billion, a price-to-earnings ratio of 17.18, a price-to-earnings-growth ratio of 0.63 and a beta of 0.39.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 29th. Investors of record on Wednesday, September 15th will be given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 4.03%. The ex-dividend date of this dividend is Tuesday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 40.06%.

In other Gilead Sciences news, CAO Diane E. Wilfong sold 13,610 shares of the stock in a transaction on Tuesday, August 17th. The stock was sold at an average price of $72.50, for a total transaction of $986,725.00. Following the sale, the chief accounting officer now directly owns 30,179 shares in the company, valued at approximately $2,187,977.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.12% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the business. Albion Financial Group UT purchased a new stake in Gilead Sciences during the 2nd quarter valued at $27,000. Massmutual Trust Co. FSB ADV boosted its stake in shares of Gilead Sciences by 138.8% in the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 394 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 229 shares during the last quarter. Sawyer & Company Inc purchased a new position in shares of Gilead Sciences in the 2nd quarter worth $28,000. Meridian Wealth Partners LLC purchased a new position in shares of Gilead Sciences in the 1st quarter worth $32,000. Finally, Elmwood Wealth Management Inc. purchased a new position in shares of Gilead Sciences in the 1st quarter worth $35,000. Institutional investors and hedge funds own 78.04% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Further Reading: How to invest in blue-chip stocks

Get a free copy of the Zacks research report on Gilead Sciences (GILD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.